Clinical trial
Safety and Tolerability Study of Extended Release (ER) Galantamine in…
NCT00082602 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00082602 |
|---|---|
| Title | Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease |
| Official title | Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho-McNeil Neurologics, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | galantamine ER |
| Enrollment | 83 |
| Start date | May 1, 2004 |
| Completion | Apr 1, 2005 |
| First posted | May 17, 2004 |
| Last update posted | May 20, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: